Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its product, Bu Xue Yi Mu Wan, to be classified as the first secondary protected traditional Chinese medicine variety, enhancing its market competitiveness in postpartum recovery medication [1]. Group 1 - The approval of Bu Xue Yi Mu Wan as a secondary protected variety strengthens the company's intellectual property protection [1]. - Bu Xue Yi Mu Wan is recognized as a national basic drug, a Class A medical insurance variety, and an exclusive product, included in various clinical application guidelines and textbooks [1]. - The product is indicated for conditions related to postpartum abdominal pain due to deficiency of both qi and blood, as well as blood stasis [1]. Group 2 - The company anticipates that this approval will positively impact its production and operations [1]. - The sales performance of the drug may be influenced by national policies and market environment changes, indicating a level of uncertainty [2].

Core Viewpoint - Qizheng Tibetan Medicine has announced that its subsidiary, Tibet Tibetan Medicine Group Co., Ltd., has received approval for its Ten Flavor Gentian Flower Capsule as the first secondary protected traditional Chinese medicine, with a protection period of seven years from the announcement date [1] Group 1: Product Approval and Market Impact - The Ten Flavor Gentian Flower Capsule is indicated for clearing heat, resolving phlegm, stopping cough, and relieving asthma, primarily used in the treatment of respiratory diseases [1] - This approval is expected to enhance the company's market competitiveness in the respiratory field [1] - The approval will also promote the upgrading of Tibetan medicine quality standards and optimization of product quality [1] Group 2: Market and Regulatory Considerations - The production and sales of the drug are subject to various factors, including market environment changes and industry policies, which introduce a degree of uncertainty [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has approved Chengdu Huasheng Technology Group Co., Ltd.'s Sanqi Tongshu Capsules as the first secondary protected traditional Chinese medicine variety, with a protection period of seven years starting from the announcement date [1][2]. Product Information - Product Name: Sanqi Tongshu Capsules - Dosage Form: Capsule - Specification: 0.2g per capsule - Indications: The product is indicated for promoting blood circulation, alleviating blood stasis, improving cerebral infarction and ischemic dysfunction, restoring ischemic brain metabolism abnormalities, preventing platelet aggregation, and improving microcirculation, primarily used for cerebrovascular embolic diseases such as stroke and hemiplegia [1][3]. Product Overview - Sanqi Tongshu Capsules are derived from the active components of the Sanqi herb, specifically the saponins, and are recognized as a new generation of Sanqi preparations. The product has multiple effects, including preventing thrombosis and promoting nerve function recovery, and has been included in various clinical guidelines for the treatment of cerebrovascular diseases. The product has received several awards for its technological advancements and its active ingredient has been recognized in international pharmacopoeias [3]. Impact on the Company - The approval of Sanqi Tongshu Capsules as a secondary protected variety enhances market protection and is expected to improve the product's core competitiveness, positively impacting the company's operations. However, the short-term impact on the company's financial performance is expected to be limited due to uncertainties in the pharmaceutical industry and market environment [4].